| Date Filed | Type | Description |
| 10/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 10/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 09/28/2023 |
8-K
| Quarterly results |
| 08/21/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/09/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/27/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Departure of Directors or Certain Officers; Election of Directors; Appointment... |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/28/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/28/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/27/2023 |
SC 13G/A
| Hu Mei Mei reports a 69.5% stake in Vaxxinity, Inc. |
| 01/27/2023 |
SC 13G/A
| UNITED BIOMEDICAL INC reports a 51.6% stake in Vaxxinity, Inc. |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/24/2022 |
8-K
| Quarterly results |
| 05/09/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/05/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/02/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/27/2022 |
SC 13G
| Hu Mei Mei reports a 69.5% stake in Vaxxinity, Inc. |
| 04/27/2022 |
SC 13G
| Reese Lou reports a 8.6% stake in Vaxxinity, Inc. |
| 04/27/2022 |
SC 13G
| UNITED BIOMEDICAL INC reports a 51.6% stake in Vaxxinity, Inc. |
| 03/28/2022 |
8-K
| Quarterly results |
| 03/24/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/21/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/09/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/04/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/23/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 11/17/2021 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financi...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : November 11, 2021 Vaxxinity, Inc. Delaware 001-41058 86-2083865 File Number) Identification No.) 1717 Main St, Ste 338 Dallas, TX, 75201 Registrant's telephone number, including area code: 244-5739 Not applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange...",
"Underwriting Agreement, by and among Vaxxinity, Inc. and BofA Securities, Inc., Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters specified therein",
"Amended and Restated Certificate of Incorporation of Vaxxinity, Inc",
"Amended and Restated Bylaws of Vaxxinity, Inc",
"Registration Rights Agreement, by and among Vaxxinity, Inc. and the “Investors,” as defined therein" |
|
|